Drug Profile
Chondroitin sulfate - Bioiberica
Alternative Names: Chondroitin sulfate CS b-Bioactive®; Chondroitin sulphate - Bioiberica; Condro-Sorb; Condrosan; Condrosulf (Bioiberica)Latest Information Update: 24 Sep 2021
Price :
$50
*
At a glance
- Originator Bioiberica
- Class Anti-inflammatories; Antirheumatics; Glycosaminoglycans
- Mechanism of Action Collagen stimulants; Leucocyte elastase inhibitors; Proteoglycan stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Musculoskeletal disorders; Osteoarthritis; Rheumatic disorders
Most Recent Events
- 24 Apr 2018 Registered for Osteoarthritis (Combination therapy) in Finland, Poland, Hungary, Austria, France (PO) through mutual recognition process from Spain
- 24 Apr 2018 Registered for Osteoarthritis (Combination therapy) in Spain (PO)
- 24 Apr 2018 Bioiberica plans to launch the combination drug of chondroitin sulphate and glucosamine hydrochloride by 2018.